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As in humans, obesity and its associated diseases represent the most significant 
threat to the health of veterinary populations. Previous human studies have provided 
insights into the risk factors of obesity, complex pathogenesis of obesity-associated 
diseases, and their life-threatening consequences. In humans, the “metabolic syn-
drome” represents a cluster of metabolic risk factors associated with the development 
of cardiovascular disease. Risk factors for metabolic syndrome, such as diabetes, 
obesity, high blood pressure, and its complications increase health-care utilization and 
medical expenses. Early diagnosis and intervention through preemptive approach is 
in need, and the new International Diabetes Federation definition of MS serves as the 
universally accepted diagnostic tool that is accessible in clinical settings. In veterinary 
populations, especially in cats, similar pathophysiological path and disease progression 
to the development of MS, such as adipokine dysregulations, chronic inflammation, 
lipotoxicity, are expected. The aim of this manuscript is twofold. First of all, it presents 
our preliminary feline obesity study that serves as the basis for discussion of obesity 
and its metabolic impact on feline population. In this study, we observed the effects of 
weight gain on energy metabolism using metabolome markers, such as adiponectin 
(ADN) and proinflammatory cytokines, in correlation with other common biochemical 
parameters in 14 clinically healthy cats of varying weight status. Further, we evaluated 
the visceral fat accumulation in three subjects of varying Body Condition Scores via 
computed tomography imaging and laparoscopic examination, and assessed the 
adipocyte type and size histologically. Mutually antagonizing changes in ADN and 
visceral adipose tissue (VAT) reflected the pathophysiological derangements leading to 
MS earlier than the common biochemical predictors such as glucose, liver values, and 
lipid markers. Second, it proposes the novel diagnostic and classification method of 
Abbreviations: ADN, adiponectin; AMPK, AMP-activated protein kinase; ALT, alanine aminotransferase; AST, aspartate ami-
notransferase; BIA, bioelectrical impedance analysis; BCS, Body Condition Score; CT, computed tomography; DEXA, c; DM, 
diabetes mellitus; GLU, glucose; IDF, International Diabetes Federation; INS, insulin; MRI, magnetic resonance imaging; MS, 
metabolic syndrome; NEFA, non-esterified fatty acid; TC, total cholesterol; TG, triglyceride; TNFα, tumor necrosis factor α; 
T2DM, type 2 diabetes mellitus; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; WC, waist circumference.
TaBle 1 | human metabolic syndrome diagnostic criteria (20).
(1) WC (cm) ≥90 (M); 80 (F) (Japanese)
(2) Triglyceride (mg/dL) >150
(3) HDL-C (mg/dL) <40 (M), 50 (F)
(4) Blood pressure (mmHg) ≥130/85
(5) FPG (mg/dL) ≥100 or with T2DM
WC, waist circumference; HDL-C, HDL-cholesterol; FPG, fasting plasma glucose;  
M, male; F, female; T2DM, type 2 diabetes mellitus.
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inTrODUcTiOn
The prevalence of obesity and its associated metabolic diseases has 
been a growing concern and has become the global epidemic in 
veterinary medicine (1–4). Obesity is an excessive accumulation 
of triglyceride (TG) in adipose tissues, due to an energy imbal-
ance where energy intake exceeds energy expenditure. Adipose 
tissue is not only a mere inert fuel storage but also an important 
secretory and endocrine organ that actively releases substances, 
“adiopokines.” Adipokines are involved in a wide array of physi-
ological processes including glucose (GLU) and lipid homeostasis, 
blood pressure, body weight regulations, and immune functions 
(5, 6). The dysregulated synthesis of “harmful” adipokines, such 
as tumor necrosis factor α (TNFα) (7), interleukin-6, and of “ben-
eficial” adipokines, such as adiponectin (ADN) (8) and leptin (9), 
is involved in the development of obesity-associated syndrome. 
Obesity-associated diseases include diabetes mellitus (DM), 
insulin (INS) resistance, lipid profile abnormalities, orthopedic 
diseases, cardiorespiratory diseases, neoplasia, and shortened 
life span (10, 11). Even before obesity-associated diseases are 
clinically apparent, evidences of oxidative stress and low-grade 
chronic inflammation are present due to increased lipid peroxi-
dation and proinflammatory adipokine secretion from growing 
adipose tissues. Increased oxidative stress affects adipokine 
production, and dysregulated production of adipokines plays a 
crucial role in the development of obesity-associated diseases (11, 
12). In humans, continued elevation of non-esterified fatty acids 
(NEFAs) results in decreased secretion of INS and dysfunction of 
pancreatic β cells, which in turn, leads to the development of DM: 
a phenomenon termed as lipotoxicity (13, 14).
One of many major consequences of obesity in humans is 
metabolic syndrome (MS). MS is defined as the set of risk factors 
associated with cardiovascular disease, one of the most serious 
lifestyle-related diseases in humans. These metabolic risk factors 
have extracted enormous burden on national health-care systems 
and budgets in an increasing numbers of countries (15) and have 
been the major focus of international research. During the late 
1980s, many studies focused on such collection of symptoms in 
order to define lifestyle diseases. Syndrome X, defined by Reaven 
(16), included INS resistance, hypertension, GLU intolerance, 
and hypertriglyceridemia. “The deadly quartet,” described by 
Kaplan (17), included GLU intolerance, hypertriglyceridemia, 
hypertension, and upper-body obesity. DeFronzo and Ferannini 
(18) recognized that INS resistance was commonly associated 
with such conditions and proposed the term “insulin resistance 
syndrome.” Then, Matsuzawa et al. (19) proposed the pathophysi-
ological importance of visceral fat deposition in the development 
of metabolic dysfunctions and introduced the term “visceral 
fat syndrome.” The above four pathophysiological concepts 
shared similar conditions such as INS resistance, GLU intoler-
ance, hypertension, hypertriglyceridemia, and obesity, and later 
referred to as the “metabolic syndrome.” In 2006, International 
Diabetes Federation (IDF) published a consensus guideline 
(20), describing a list of diagnostic criteria for MS (Table  1). 
The diagnostic criteria included waist circumference (WC), 
TG, cholesterol, GLU concentrations, blood pressure, and the 
reference values for each criterion. In humans, each component 
of MS is an independent risk factor for arteriosclerosis, chronic 
kidney disease, and non-alcoholic steatohepatitis (21). A set of 
MS diagnostic criteria is a useful tool in preventative medicine as 
it alerts for an implementation of early environmental, medical, 
and lifestyle interventions.
As in humans, obesity-associated diseases and metabolic 
abnormalities are common in dogs and cats (22, 23). Similar 
pathophysiological path and disease progression to the develop-
ment of MS are expected in companion animals. In cats, obesity 
is associated with the development of INS resistance (24) and 
type 2 diabetes mellitus (25–28) and is considered a good human 
MS model (29). Whereas in dogs, symptoms such as obesity, 
hyperglycemia, and hyperlipidemia are commonly seen but are 
not considered to directly precede the development of INS resist-
ance and DM (30) In fact, over 50% of DM cases in dogs are type 
1, whereas type 2 is much more common in feline (80–95% DM 
cases) (31). Therefore, the use of the term “metabolic syndrome” 
in dogs can be considered a misconception (30, 32).
Such species-difference is due to the unique characteristics 
of feline GLU and lipid metabolism (33). Cats lack one of the 
rate-limiting enzymes that mediate glycolysis in the liver (34). 
Hexokinases mediate the conversion of GLU to GLU-6-phosphate 
as the first step of glycolysis. Hexokinases I–III are present in cats 
as in dogs and are most active in low blood GLU concentration. 
Unlike in dogs, lack of hexokinase IV (glucokinase) in cats 
causes inability to process blood GLU at high concentration and 
a subsequent accumulation of excess energy as TG in adipose 
feline obesity and MS, based on the established diagnostic criteria of human MS and 
the presented study results. The results supported our novel “classification of feline 
obesity” and “Feline MS diagnostic criteria,” suggesting the need to complement ADN 
measurement with VAT volume to better understand the pathogenesis of metabolic 
disturbances in the feline population.
Keywords: feline obesity, metabolic syndrome, adiponectin, visceral adipose tissue, tumor necrosis factor α, 
lipotoxicity, obesity classification
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tissues. Additionally, the expression levels of mRNA associated 
with INS signaling pathway, such as INS receptor substrate-1, INS 
receptor substrate-2, phosphatidylinositol 3-kinase P-85 alpha in 
classical INS-responsive tissues, were significantly lower in cats 
when compared to those in dogs (35). Furthermore, ADN, an 
adipokine that improves INS sensitivity, was also lower in cats 
at normal state (35) and with weight gain (36). Unlike in dogs 
that maintain circulating ADN even with weight gain (36), ADN 
seems to play more important role in the development of obesity-
related metabolic disturbances in cats. Together, these evidences 
suggest that cats inherently have lower ability to process GLU, 
are predisposed to obesity and INS resistance, and to visceral 
obesity-induced lipid metabolism abnormality just as in humans.
In humans, early detection and intervention of weight gain 
is crucial under the management of preemptive and preven-
tive medicine. It is advised that weight status and health status 
of at-risk individuals be closely monitored using quantitative 
parameters such as body mass index (BMI) (37, 38), blood pres-
sure, cholesterol and GLU levels, and WC size as instructed by 
IDF guidelines (20). Many publications and organizations offer 
helpful guidelines to promote healthy lifestyle changes including 
healthy eating, moderate exercise, and stress reduction (39–42). 
However, in veterinary medicine, there is no consensus on objec-
tive biochemical and mechanical parameters and their reference 
values to classify the weight status. A commonly accepted evalu-
ation method of weight status is Body Condition Score (BCS) (43, 
44), which is a semi-quantitative assessment method employing 
subjective visual observation and palpation of an observer. Such 
evaluation method is a useful initial screening tool, but subject 
to interobserver variations and underestimation of the body fat 
level. Furthermore, it does not reflect the true metabolic and 
health status of a companion animal because it does not directly 
measure adipose status. Many evidences suggest the significance 
of adipose status, such as adipose depot distribution (subcutane-
ous vs visceral) and adipocyte size (small vs large) in adipokine 
synthesis and metabolic health (8, 45). In humans, anthropomet-
ric measurements such as BMI and WC are considered to cor-
relate well with adipose status (46, 47), but such measurements 
are not yet available in veterinary medicine. Quantitative, objec-
tive measurement methods of body composition in companion 
animals have been researched in scientific studies. They include 
ultrasound imaging, computed tomography (CT), magnetic 
resonance imaging, dual-energy X-ray absorptiometry (DEXA), 
bioelectrical impedance analysis (BIA), and deuterium oxide 
dilution method (48, 49) They show good reliability in determin-
ing body composition in dogs and cats, but highly inaccessible 
in veterinary practices. Additionally, most of them measure total 
body fat and do not quantitatively distinguish between subcu-
taneous adipose tissue (SAT) and visceral adipose tissue (VAT). 
Previously, many researchers have introduced various quantita-
tive parameters such as lipid concentrations (50, 51), lipoprotein 
profiles (52, 53) oxidized low-density lipoprotein (54), and their 
reference values to evaluate the quality of weight gain.
Practical methods of overweight/obesity diagnosis and clas-
sification, employing such measurable biochemical parameters, 
which reliably reflect adipose status, true metabolic and health 
status in cats, are in need.
The aim of this manuscript is twofold. First, it presents our 
preliminary feline obesity study evaluating biochemical and 
mechanical changes associated with weight gain. In this study, 
we observed the effects of weight gain on energy metabolism 
using metabolome markers, such as ADN and proinflamma-
tory cytokines in correlation with other common biochemical 
parameters in 14 clinically healthy cats of varying BCS. Further, 
we evaluated the visceral fat accumulation via CT imaging and 
laparoscopic examination and assessed adipocyte type and size 
histologically in three cats of varying BCS. Second, it proposes the 
novel diagnostic and classification method of feline obesity and 
MS, based on the established diagnostic criteria of human MS 
and our preliminary study data. A set of objective, quantitative 
biomarkers necessary for early diagnosis and classification of 
feline obesity is introduced. By defining stage, degree, and quality 
of weight gain, a guide for interventions (exercise, therapeutic 
diet, and medications) appropriate for each stage of weight status 
can be established. Together, they present a feline-specific clas-
sification of obesity and MS.
aniMals anD MeThODs
animals
Sixteen client-owned cats (0–16 years old; female: n = 5; male: 
n = 11) of varying BCS from 6 veterinary hospitals in Kanto area 
were entered into the study. After medical evaluation, clinically 
healthy 14 subjects were assigned to 4 groups based on the 5-point 
scale BCS system (31, 32) described as follows: BCS 1, very thin; 
BCS 2, underweight; BCS 3, ideal; BCS 4, overweight; and BCS 
5, obese. Seven subjects fell into the BCS 3 category, five subjects 
in BCS 4, and two subjects were in BCS 5. Ethical approval was 
obtained from the Nippon Veterinary and Life Science University 
Animal Research Committee. Informed consent was obtained 
from each client.
Plasma analysis
Pre-prandial blood was collected from jugular vein into heparin-
ized plastic tubes. These samples were immediately centrifuged at 
1,700 × g for 10 min at 4°C to obtain plasma, and the samples were 
stored at −80°C until use. Plasma GLU, TG, total cholesterol (TC) 
concentrations and plasma aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) activities were measured using 
autoanalyzer (JCA-BM2250, JEOL Ltd., Tokyo, Japan) with the 
manufacturer’s reagents at Monolis Inc., Tokyo, Japan. Plasma 
non-esterified fatty acid (NEFA) concentrations were measured 
with a commercial kit (NEFA-C test, Wako Pure Chemical 
Industries, Ltd., Tokyo, Japan). Plasma INS and ADN concentra-
tions were measured with a commercial kit (Cat Insulin ELISA 
kit, Shibatagi Co., Ltd., Gunma, Japan; Mouse/Rat Adiponectin 
ELISA kit, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan), 
respectively. Statistical analysis for plasma parameters was per-
formed by Mann–Whitney U-test (p < 0.01).
laparoscopic evaluation
Laparoscopic abdominal evaluations of three representative feline 
subjects (one each from BCS 3, 4, and 5 groups) were performed. 
TaBle 2 | comparison of plasma parameters between cats of Body 
condition score (Bcs) 3, 4, and 5 groups.
Bcs 3 (7) Bcs 4 (5) Bcs 5 (2)
Glucose (mg/dL) 102.9 ± 6.7 114.0 ± 16.4 97
Insulin (ng/mL) 1.3 ± 0.1 1.3 ± 0.1 1.8
Triglyceride (mg/dL) 30.0 ± 10.3 48.8 ± 9.0 121.5
Total cholesterol (mg/dL) 149.9 ± 41.6 166.2 ± 12.0 138.0
NEFA (mEq/L) 0.270 ± 0.003 0.295 ± 0.051 0.327
AST (IU/L) 27.4 ± 2.5 29.2 ± 2.1 20
ALT (IU/L) 42.1 ± 4.6 46.8 ± 5.0 54.0
Adiponectin (μg/mL) 10.1 ± 1.6 2.5 ± 0.7* 0.6 (1)
Tumor necrosis factor α (pg/mL) 117 ± 41 (6) 140 ± 38 (4) 1,346 (1)
Data of BCS 3 and 4 are presented as mean ± SE.
Data of BCS 5 are presented as mean.
The numbers in parentheses indicate the number of animals examined.
*Significantly different from the values BCS 3 by Mann–Whitney U-test, p < 0.01.
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Each subject was premedicated with intravenous injections of 
atropine sulfate at a dose of 0.025 mg/kg, butorphanol at 0.1 mg/
kg, diazepam at 0.3 mg/kg, and cefazolin at 20 mg/kg. Anesthetic 
induction was done using thiopental sodium injection (12.5 mg/
kg) and maintained with 2% end-tidal concentration of isoflurane 
administered via endotracheal intubation. Intraoperatively, each 
subject was administered intravenous fluids at a maintenance 
dose.
Laparoscopic procedure was performed as described previ-
ously (55) using rigid telescope 30° (KARL STORZ Endoscopy 
Japan, Tokyo), 5  mm trocar–cannulas (Olympus Medical 
systems, Tokyo), light sources (Xenon nova 175, KARL STORZ 
Endoscopy Japan, Tokyo), automatic carbon dioxide (CO2) 
insufflator (Electronic Endoflator, KARL STORZ Endoscopy 
Japan, Tokyo), and video imaging systems (LMD-2450 MD, 
Sony Corporation, Tokyo). A two-port entry ventral midline 
approach was performed with a telescope placed through the 
first 5-mm-cannula at 1 cm caudal to the umbilicus. The second 
3-mm cannula was placed at 2–3 cm lateral to the midline on 
either side. With the use of 5-mm cup biopsy forceps, the edge 
of a liver lobe was gently grabbed, twisted, and retracted toward 
the instrument port. Care was taken to avoid rough handling 
that may lead to excessive hemorrhage and tearing. The same 
procedure was repeated for intraabominal fat (omental fat). 
Subcutaneous fat was collected at the time of trocar insertion at 
the site of abdominal incision.
cT imaging
The same three subjects used for laparoscopic evaluation were 
maintained under anesthesia as described above for CT imaging 
of the abdomen. All CT images were obtained using a multi-slice 
CT (BrightSpeed 8 rows, GE Healthcare, Tokyo, Japan). Imaging 
conditions were as follows: a tube voltage of 120 kV, tube current of 
118 mA, and imaging slice thickness of 1.25 mm. Scanned images 
were reconstructed by RETRO recon reconstruction function of 
the CT scanner, then processed using a built-in scanner.
Biopsy Tissues
Parts of liver, omental, and subcutaneous fat were fixed with 10% 
neutral-buffered formalin and embedded in paraffin wax. Cut 
sections (4 µm) were stained with hematoxylin and eosin (HE) 
for histological examination. Formalin-fixed tissues were also 
frozen, sectioned at 10-µm thickness, and stained with oil red 
O. Specimen preparation and histopathological evaluation were 
performed by one clinical pathologist.
resUlTs
Table 2 shows the results of plasma biochemical measurements. 
Mean concentration of ADN in BCS 3 cats was significantly 
higher than those in BCS 4. ADN concentration of 1 subject in 
BCS 5 showed over 16-fold and 4-fold decrease compared to 
those in BCS 3 and BCS 4 groups, respectively. Conversely, TNFα 
concentration of BCS 5 (1 subject) was over 11-times and 9-times 
higher than those in BCS 3 and BCS 4, respectively. Similarly, 
TG and NEFA concentrations showed increasing tendency with 
increasing weight status.
Figure 1 shows three representative cross-sectional CT images 
(BCS 3, 4, and 5) at the level of renal pelvis. Fat mass, appearing as 
black image (blue arrow), is visibly thicker in overweight (BCS 4) 
and obese (BCS 5) cats than in ideal cat (BCS 3), occupying more 
space relative to the abdominal organs. Furthermore, subcutane-
ous fat represented by arrow head is visibly thicker in BCS 5 than 
in BCS 4, and in BCS 4 than in BCS 3.
Figure  2 shows the side-by-side comparison of histological 
images of liver as follows: (A) normal cat liver, oil red O stained; 
(B) obese cat liver, oil red O stained. As evident, there is no 
significant finding noted in normal cat liver sample. In obese 
cat liver, there is an increase in small lipid droplets (shown in 
orange color, oil o red) at lobular margin. Final histopathological 
diagnosis was concluded as “lipid droplet accumulation in lobu-
lar marginal hepatocytes with no signs of hepatic lipidosis” in 
obese cat (BCS 5). The liver was accumulating lipids but was not 
showing pathology as evidenced by the normal activity levels of 
ALT and AST.
Figure 3 shows the side-by-side comparisons of HE-stained 
histological images of subcutaneous and intra-abdominal 
(omental) fat as follows: (A) normal cat subcutaneous fat, (B) 
obese cat subcutaneous fat, (C) normal cat omental fat, and 
(D) obese cat omental fat. Regardless of fat location, there 
were visibly less adipocytes per field in obese cat samples 
and larger size adipocytes compared to those in normal cat 
samples.
DiscUssiOn
In our preliminary feline study, changes in adipose depot distri-
bution and adipocyte sizes in correlation with changes in BCS 
and metabolome markers were evaluated.
The results showed that with increasing BCS, body fat distri-
bution and adipocyte size shifted from subcutaneous to visceral, 
and small to large size, respectively. Previous studies suggest 
the significance of adipose depot distribution (subcutaneous vs 
visceral) and adipocyte size (small vs large) and age (immature vs 
mature) (56) in ADN synthesis and secretion (8, 41).
Evidently, our overweight/obese subjects showed lower 
circulating ADN concentration and more TNFα concentration, 
FigUre 1 | comparison of cross-sectional abdominal computed 
tomography (cT) images at the level of renal pelvis among Bcs 3, 4, 
and 5 cats. Cross-sectional abdominal CT images at the level of renal pelvis 
are presented: (a) BCS 3 cat; (B) BCS 4 cat; and (c) BCS 5 cat. Arrows 
point to intra-abdominal area (visceral fat), and arrowheads point to 
subcutaneous area. Note with increasing BCS, visceral fat (appeared as 
black area, arrow) volume increases, occupying more spaces relative to 
abdominal organs. Subcutaneous fat depot (arrow head) also increases with 
increasing BCS.
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showing the mutually antagonizing relationship of ADN and 
TNFα in concordance with the previous studies (57–59). The 
decline in ADN concentration, and increase in adipocyte hyper-
trophy and VAT appeared earlier than changes in liver tissues 
and common biochemical predictors, such as GLU, liver values, 
and lipid markers, were evident. Decline in ADN, “beneficial 
adipokine,” and elevation in TNFα, “harmful adipokine,” in 
overweight and obese cats, with visceral fat accumulation and 
adipocyte hypertrophy, support the positive correlation between 
visceral obesity, metabolic disturbances, and degree of pathology 
in feline obesity.
Based on our preliminary study data and previously estab-
lished human diagnostic criteria (Table 1), we further propose a 
new “Feline metabolic syndrome diagnostic criteria” (Table 3) 
and a novel “classification of feline obesity” (Figure 4). Note 
that central (abdominal) obesity, which is easily assessed by 
WC in humans, is replaced by BCS. Furthermore, we added 
ADN as the last criterion as an indicator of visceral fat volume 
(central obesity) and metabolic health. Unlike in humans, 
evaluation of weight status using height (m) and weight (kg), 
as described by BMI, is not practical in cats due to the breed 
and conformation variations. Instead, 5 or 9 scale BCS (43, 
44) is used. In our new classification (Figure  4), “secondary 
obesity” denotes weight gain induced by endocrine or genetic 
causes. It requires medical management of underlying dis-
eases and is beyond the scope of this manuscript. “Primary 
obesity” is of our interest and is further divided into “simple” 
and “pathological” obesity (obesity disease) based on the 
presence of obesity-associated symptoms. “Obesity disease” is 
then divided into “visceral fat obesity” and “subcutaneous fat 
obesity” based on the location of adipose tissue depot. With 
progressive and excessive accumulation of VAT, cats are at a 
higher risk of developing MS. In humans, WC is considered a 
strong predictor of intra-abdominal fat (visceral fat). In cats, 
ADN concentration is suggested as the biomarker for visceral 
fat accumulation associated with MS.
Adiponectin is a cytokine secreted by adipocytes. It is 
involved in GLU and lipid metabolism and exerts direct effects 
on vasculatures, thus positively influences the metabolic health 
of individuals (27). It modulates the expression of fatty acid 
transport proteins in liver and skeletal muscle and stimulates 
fatty acid oxidation and GLU utilization via activation of AMP-
activated protein kinase (AMPK) (60). AMPK is a sensor of 
cellular energy status and mediates the effects of adipokines in 
food intake, body weight, and GLU and lipid metabolism (61). It 
has protective effects against obesity and INS resistance (61, 62). 
Additionally, AMPK activation suppresses oxidative stress and 
inflammatory processes, which are the characteristics commonly 
seen in obese individuals. ADN also exerts anti-inflammatory 
actions via inhibition of macrophage activity and C-reactive 
protein, TNFα production, and action. It is considered the 
“beneficial” adipokine, and its decline in plasma is associated 
with disease processes, such as obesity, INS resistant type 2 
diabetes, and coronary artery disease in humans (7, 27). Unlike 
other adiopokines, secretion and circulating levels of ADN are 
inversely proportional to body fat mass (63). Low level of cir-
culating ADN is associated with obesity and MS (5). Generally, 
it is considered to circulate at levels inversely proportional to 
body fat content. In fact, ADN concentration increases with an 
increase in SAT, which generally consists of small adipocytes 
(64) but decreases with increased visceral fat accumulation 
(8, 45). Therefore, low circulating ADN is considered a strong 
predictor of visceral fat obesity, associated with GLU and lipid 
metabolism abnormalities, and can be used as the diagnostic 
tool for MS.
TaBle 3 | Feline metabolic syndrome diagnostic criteria.
(1) Body Condition Score >3.5/5 or 5/9
(2) Fasting glucose (mg/dL) >120
(3) Triglyceride (mg/dL) or total cholesterol (mg/dL) >165 or >180
(4) Adiponectin (μg/mL) <3.0
FigUre 3 | histological comparison of subcutaneous and omental fat between normal [Body condition score (Bcs) 3] and obese (Bcs 5) cats: (a) 
omental fat, Bcs 3; (B) ometal fat, Bcs 5; (c) subcutaneous fat, Bcs 3; and (D) subcutaneous fat, Bcs 5. Note the increased adipocyte size (emphasized 
with dotted lines) and decreased number of adipocytes with increased BCS.
FigUre 2 | histological comparison of biopsied liver tissues between normal [Body condition score (Bcs) 3] and obese (Bcs 5) cats (oil o red 
stained): (a) Bcs 3 (B) Bcs 5. Note the increased level of lipid droplets (stained in red) in BCS 5 liver tissue.
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cOnclUsiOn
As for many other non-communicable diseases, the optimal 
management of MS is prevention. Successful identification of risk 
factors and classification of feline obesity can be useful guides 
when establishing early intervention and management. Our 
study results support our novel “classification of feline obesity” 
(Figure 4) and “Feline metabolic syndrome diagnostic criteria” 
(Table  3), suggesting the need to complement ADN measure-
ment with VAT volume to better understand the pathogenesis 
of metabolic disturbances in the feline population. Changes in 
ADN and VAT seemed to reflect the pathophysiological derange-
ments leading to MS much earlier than the common biochemical 
predictors such as GLU, liver values, NEFA, TG, and TC.
This was a preliminary study to validate our novel classification 
and diagnostic criteria of feline obesity and MS. Limitations of our 
study include small number of samples and biological and envi-
ronmental variables (age, genetics, diet, and exercise), which are 
inevitable when client-owned animals are utilized. Also, there is no 
established reference value for feline ADN, thus we used compari-
son of values among individuals from various BCS. Furthermore, 
AB
C
FigUre 4 | classification of feline obesity. A flow chart showing classification of feline obesity as a guide for early diagnosis and intervention. Obesity is 
classified by (a) its cause, (B) presence of associated disease, and (c) location of fat depot.
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in this study, changes in amounts of SAT and VAT, adipocyte size, 
and numbers were only visually evaluated. More refined quantita-
tive studies employing direct measurement of adipocytes (45), BIA 
(65), DEXA (66), or special calculations to measure SAT and VAT 
volumes (67) on controlled subjects should be performed in the 
future. In human medicine, a combination of CT scanning and 
body fat analysis software is often utilized to measure body fat in 
MS management. No such software specialized for body fat meas-
urement has been developed for veterinary subjects. However, the 
application of human body fat analysis software has been shown 
to be useful in a study conducted by Kobayashi et al. (67). Such 
further studies will help establish reference values for feline ADN 
concentration and VAT volume that reflect the degree of pathology.
Metabolic syndrome represents a cluster of medical condi-
tions and is considered an optimal target of preemptive medicine. 
In preemptive medicine, multifaceted factors such as genomics, 
metabolomics, and environmental associations need to be eluci-
dated. Establishment of diagnostic criteria based on such data will 
facilitate early diagnosis and interventions and may serve as an 
established model in the field of veterinary preemptive medicine.
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